

## **Boston Scientific Receives 2005 Best Practices in Logistics Management Gold Award**

(July 28, 2005) -- Boston Scientific Corporation (NYSE: BSX) today announced that it has received the 2005 Best Practices in Logistics Management Gold Award from Logistics Management magazine, a leading publication for supply chain professionals. The award recognizes Boston Scientific's successful efforts to increase efficiencies in the global supply chain of its market leading TAXUS® Express<sup>2</sup>™ paclitaxel-eluting coronary stent system.

The annual Best Practices Awards recognize companies that have developed innovative and effective approaches to managing logistics. This year, editors at Logistics Management magazine evaluated more than 70 entries and chose Boston Scientific as the sole Gold Award winner for its ability to improve transit times for TAXUS by 32 percent while increasing product shipment capacity by 167 percent and reducing airfreight costs by 17 percent.

"This highly regarded award acknowledges our commitment to increasing efficiency and reducing costs throughout our supply chain," said Paul LaViolette, Boston Scientific Chief Operating Officer. "Through better collaboration across disciplines and improved communications, we were able to significantly reduce our TAXUS transit times, allowing our products to reach patients sooner."

Boston Scientific is featured in the cover story of the June issue of Logistics Management magazine.

To date, Boston Scientific has shipped approximately 1.6 million TAXUS Express<sup>2</sup> paclitaxel-eluting coronary stent systems worldwide.

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: [www.bostonscientific.com](http://www.bostonscientific.com).

This press release contains forward-looking statements. Boston Scientific wishes to caution the reader of this press release that actual results may differ from those discussed in the forward-looking statements and may be adversely affected by, among other things, risks associated with new product development and commercialization, supply chain management, Boston Scientific's overall business strategy, and other factors described in Boston Scientific's filings with the Securities and Exchange Commission.

---

<https://news.bostonscientific.com/news-releases?item=58771>